iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
  Download the PDF here
Clinical Infectious Diseases Advance Access published March 29, 2016
Anne F. Luetkemeyer1, Cheryl McDonald2, Moti Ramgopal3, Stephanie Noviello4, Rafia Bhore5, Peter Ackerman6
Highly-effective hepatitis C virus (HCV) direct-acting antiviral therapies are needed that do not require modification of human immunodeficiency virus (HIV) antiretroviral regimens. This analysis evaluates the efficacy and safety of the combination of daclatasvir+sofosbuvir (DCV+SOF) for 12 weeks by antiretroviral regimen in HIV-HCV coinfected patients.
Methods. In the randomized, open-label ALLY-2 study (NCT02032888), HIV-HCV coinfected patients received 8 or 12 weeks of once-daily (QD) DCV 60mg+SOF 400mg. Results were stratified by antiretroviral class for the 151 patients who received 12 weeks of DCV+SOF.
Results. Fifty-one patients were HCV treatment-experienced, 100 were treatment-naïve, 89% were male, 33% were black. HCV genotypes were GT1a (69%), GT1b (15%), GT2 (8%), GT3 (6%), GT4 (2%). Sustained virologic response 12 weeks post-treatment (SVR12) was 97% and was similar across antiretroviral regimens (p=0.774): protease inhibitor-based, 97% (95% CI: 90%-99.7%); non-nucleoside reverse transcriptase inhibitor-based, 100% (95% CI: 91%-100%); and integrase inhibitor-based, 95% [95% CI: 83%-99.4%]). SVR12 by NRTI backbone containing either tenofovir disoproxil fumarate or abacavir was 98% [95% CI: 93%-99.5%] and 100% [95% CI: 85%-100%], respectively. Age, gender, race, cirrhosis, HCV treatment history, HCV genotype, baseline HCV viral load and CD4 cell count did not affect SVR12. HIV virologic control was not compromised. There were no treatment-related serious adverse events (SAEs) or AEs leading to discontinuation.
Conclusion. DCV+SOF QD for 12 weeks led to high SVR rates (97%) across a broad range of antiretroviral regimens and was safe and well tolerated. DCV+SOF is a highly efficacious, all-oral, pangenotypic HCV treatment for HIV-HCV coinfection.

  iconpaperstack View Older Articles   Back to Top   www.natap.org